CD8A and rheumatic heart disease: Thus, the drug increased the levels of CD3+ cells and activated CD69 cells in bronchial asthma [16], and the levels of CD3+, CD4+ and CD8+ T-lymphocytes in chronic rheumatic heart disease [17].